The global antipsychotic drugs market was valued at $12,417.60 million in 2020, and is estimated to reach $26,041.00 million by 2030, growing at a CAGR of 8.0% from 2021 to 2030.
Antipsychotics, also known as neuroleptics, are a class of psychotropic medication primarily used to manage psychosis, principally in schizophrenia and also in a range of other psychotic disorders. Antipsychotics are also the mainstay together with mood stabilizers in treatment of bipolar disorder.
The key factor driving the market growth include rise in awareness and focus on mental illness, increase in depression due to stressed lifestyle, and rise in number of mental hospitals. According to the World Health Organization (WHO), in 2018, globally more than 300 million individuals suffered from depression. The considerably large number of people suffering from mental stress increases demand for antipsychotic drugs. However, side effects such as weight gain, increasing cholesterol levels, and risk of diabetes caused due to antipsychotic drugs hamper the market growth.
Government initiatives for mental illness are expected to boost growth of the global antipsychotic drugs market, offering expansion opportunities for market competitors. For instance, in 2017, the Centers for Medicare and Medicaid introduced the psychiatric Collaborative Care Model (CoCM) and Behavioral Health Integration (BHI) under the Chronic Care Management (CCM) services initiative.
Rise in prevalence of mental health disorders, such as schizophrenia and bipolar disorder amongst the population is a major growth driver for the market. As per the Anxiety and Depression Association of America, Anxiety disorder is the most common mental illness in the U.S, affecting 40 million adults aged 18 and older, or 18.1% of the population every year. Nearly one-half of those diagnosed with depression are also diagnosed with an anxiety disorder.
World Health Organization (WHO) has recommended mental health action plan to promote mental health and preventing mental disorders in the member states. In addition, according to the key facts published by the WHO, an estimated 300 million people are affected by depression, and 60 million people are affected by bipolar disorder, across the globe. Anxiety disorders are the most communal psychiatric illnesses affecting children and adults. It is evaluated that 44 million American grown-ups experience ill effects of uneasiness issue. Merely, about one-third of those suffering from an anxiety disorder receive treatment, even though the disorders are highly treatable. Therefore, it is indicated that the market is majorly driven by rise in prevalence of mental disorders.
The global antipsychotic drugs market is segmented into therapeutic class, application, distribution channel, and region. By therapeutic class, the market is categorized into first-generation and second-generation. By application, it is categorized into schizophrenia, dementia, bipolar disorder, depression and others. By distribution channel, it is divided into a hospital pharmacies, retail pharmacies, and online pharmacies.
Some of the major companies that operate in the global antipsychotic drugs market are Eli Lily and Company, AstraZeneca plc, GlaxoSmithKline plc, Johnson & Johnson, Otsuka Pharmaceutical Co, Ltd., Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, Teva Pharmaceuticals, and Dr. Reddy's Laboratories.
Antipsychotics, also known as neuroleptics, are a class of psychotropic medication primarily used to manage psychosis, principally in schizophrenia and also in a range of other psychotic disorders. Antipsychotics are also the mainstay together with mood stabilizers in treatment of bipolar disorder.
The key factor driving the market growth include rise in awareness and focus on mental illness, increase in depression due to stressed lifestyle, and rise in number of mental hospitals. According to the World Health Organization (WHO), in 2018, globally more than 300 million individuals suffered from depression. The considerably large number of people suffering from mental stress increases demand for antipsychotic drugs. However, side effects such as weight gain, increasing cholesterol levels, and risk of diabetes caused due to antipsychotic drugs hamper the market growth.
Government initiatives for mental illness are expected to boost growth of the global antipsychotic drugs market, offering expansion opportunities for market competitors. For instance, in 2017, the Centers for Medicare and Medicaid introduced the psychiatric Collaborative Care Model (CoCM) and Behavioral Health Integration (BHI) under the Chronic Care Management (CCM) services initiative.
Rise in prevalence of mental health disorders, such as schizophrenia and bipolar disorder amongst the population is a major growth driver for the market. As per the Anxiety and Depression Association of America, Anxiety disorder is the most common mental illness in the U.S, affecting 40 million adults aged 18 and older, or 18.1% of the population every year. Nearly one-half of those diagnosed with depression are also diagnosed with an anxiety disorder.
World Health Organization (WHO) has recommended mental health action plan to promote mental health and preventing mental disorders in the member states. In addition, according to the key facts published by the WHO, an estimated 300 million people are affected by depression, and 60 million people are affected by bipolar disorder, across the globe. Anxiety disorders are the most communal psychiatric illnesses affecting children and adults. It is evaluated that 44 million American grown-ups experience ill effects of uneasiness issue. Merely, about one-third of those suffering from an anxiety disorder receive treatment, even though the disorders are highly treatable. Therefore, it is indicated that the market is majorly driven by rise in prevalence of mental disorders.
The global antipsychotic drugs market is segmented into therapeutic class, application, distribution channel, and region. By therapeutic class, the market is categorized into first-generation and second-generation. By application, it is categorized into schizophrenia, dementia, bipolar disorder, depression and others. By distribution channel, it is divided into a hospital pharmacies, retail pharmacies, and online pharmacies.
Some of the major companies that operate in the global antipsychotic drugs market are Eli Lily and Company, AstraZeneca plc, GlaxoSmithKline plc, Johnson & Johnson, Otsuka Pharmaceutical Co, Ltd., Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, Teva Pharmaceuticals, and Dr. Reddy's Laboratories.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global antipsychotic drugs market to identify the prevailing opportunities.
- This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Region & country wise analysis is provided to understand the market trends and dynamics
KEY MARKET SEGMENTS
By Therapeutic Class
- First-generation
- Second-generation
By Application
- Schizophrenia
- Dementia
- Bipolar Disorder
- Depression
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
KEY MARKET PLAYERS
- Eli Lily and Company
- AstraZeneca plc
- GlaxoSmithKline plc
- Johnson & Johnson
- Otsuka Pharmaceutical Co, Ltd.
- Pfizer Inc.
- AbbVie Inc.
- Bristol-Myers Squibb
- Teva Pharmaceuticals
- Dr. Reddy's Laboratories
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS
CHAPTER 5: ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION
CHAPTER 6: ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: ANTIPSYCHOTIC DRUGS MARKET, BY REGION
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 187 |
| Published | September 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 12417.6 million |
| Forecasted Market Value ( USD | $ 26041 million |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
